Sophia Abene

The Louisiana Department of Health announced the news late yesterday, and it is the first death in the US associated with the H5N1 virus.

A case series of 13 patients suggests that extended courses of Paxlovid could benefit some Long COVID patients, but the results are inconsistent.

Recent study highlights Paxlovid’s ability to reduce hospitalizations and mortality in high-risk populations, but underscores the need for personalized treatment.

This week, the CDC MMWR highlights a major blastomycosis outbreak and increased tularemia cases, CHOP's feedback reports improve antibiotic stewardship in pediatric pneumonia, and more.

New recommendations emphasize shorter, all-oral regimens for both drug-susceptible and drug-resistant TB.

Systematic reviews and localized studies reveal rising resistance rates in pediatric H pylori infections, highlighting the need for improved diagnostics and treatment approaches.

The largest blastomycosis outbreak linked to a paper mill in Michigan and a 56% increase in tularemia cases over the past decade.

Exploring the challenges and strategies for combating MDR Pseudomonas aeruginosa infections, as discussed with Jason Pogue, PharmD, BCPS, BCIDP

Charlotte Allerton explains how ibuzatrelvir, a second-generation treatment, could reduce drug interactions and taste disturbances compared to PAXLOVID, offering a simplified approach for high-risk patients.

Jason M Pogue, PharmD, BCPS, BCIDP discussed ceftolozane tazobactam’s effectiveness over ceftazidime avibactam, particularly in pneumonia patients, where it reduced the likelihood of recurrent infections.

6.4% of US adults experience Long COVID, with 19.8% reporting significant activity limitations, while the updated RECOVER study refines the classification index.

This week, recent studies show progress in healthcare, including an mRNA vaccine for C difficile, the rise of antimicrobial resistance, peer-assisted telemedicine for hepatitis C in rural areas, and more.

Jason M Pogue, PharmD, BCPS, BCIDP discusses the findings, pharmacokinetics, why ceftolozane-tazobactam may be the preferred choice for resistant infections, and more.

Study shows this could reduce hepatitis C and injection-related infections, with each dollar invested saving $2 in treatment costs.

Governor Newsom declares support for state response as bird flu spreads across the US among dairy cows and humans, with California leading the nation in cases.

143 deaths and 592 cases confirmed in Kwango Province, with concerns about treatment access, drug resistance, and more.

Joseph Zackular, PhD highlights targeting high-risk groups for vaccination and shares insights into the future of mRNA vaccine development for C diff.

Prenatal antibiotic use may increase the risk of asthma, food allergies, and obesity, underscoring the need for careful antibiotic stewardship during pregnancy.

Joseph Zackular, PhD suggests that mRNA vaccines and monoclonal antibodies could offer more effective treatments for recurrent C difficile infections

Joseph Zackular, PhD, shares insights on his team’s mRNA vaccine research for C difficile, highlighting progress in animal models and future plans for human trials.

Health officials are investigating an outbreak called "Dinga Dinga," which causes fever and uncontrollable shaking.

This week, evolving COVID-19 inpatient care protocols with ECMO and remdesivir, FDA breakthrough designation for a rapid sepsis test, E coli outbreak linked to iceberg and romaine lettuce, and more.

The development of CRMA-1001, a potential functional cure for chronic hepatitis B and D, is set to enter clinical trials in 2025.

P aeruginosa is found in 11.6% of diabetic foot infection cultures from hot, humid climates.

Sexual transmission was confirmed for nine of the 22 viruses studied, including Ebola, Zika, and mpox, making it a key factor in ongoing disease spread.

Alba Azola, MD discusses the challenges of diagnosing and managing Long COVID and its overlap with ME/CFS, emphasizing the need for individualized care and ongoing research.

Navigating the long road of Long COVID involves more than recovering from an infection; it requires specialized, multifaceted care to address ongoing and often invisible neurological symptoms.

Interim findings from the STOMP trial reveal that tecovirimat does not significantly accelerate lesion resolution or reduce pain in mild to moderate mpox cases.

Study found that VRE colonization is linked to higher mortality, increased need for mechanical ventilation, and renal replacement therapy, while MRSA and C diff colonization showed less impact.

If confirmed by the CDC, these cases would increase the national total of human infections to 60, with 58 already reported in various states.